Novacyt (NCYT) Competitors

EKF Diagnostics (LON:EKF) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Does the MarketBeat Community prefer EKF or NCYT?

EKF Diagnostics received 291 more outperform votes than Novacyt when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 58.06% of users gave Novacyt an outperform vote.

Company	Underperform	Outperform
EKF Diagnostics	Outperform Votes 327 76.76%	Underperform Votes 99 23.24%
Novacyt	Outperform Votes 36 58.06%	Underperform Votes 26 41.94%

Is EKF or NCYT more profitable?

EKF Diagnostics has a net margin of 9.37% compared to Novacyt's net margin of -203.06%. EKF Diagnostics' return on equity of 7.03% beat Novacyt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	9.37%	7.03%	5.27%
Novacyt	-203.06%	-47.73%	-27.98%

Do institutionals and insiders hold more shares of EKF or NCYT?

70.3% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 0.1% of Novacyt shares are owned by institutional investors. 5.2% of EKF Diagnostics shares are owned by insiders. Comparatively, 3.1% of Novacyt shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the media prefer EKF or NCYT?

In the previous week, EKF Diagnostics and EKF Diagnostics both had 1 articles in the media. Novacyt's average media sentiment score of 1.53 beat EKF Diagnostics' score of -1.04 indicating that Novacyt is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
EKF Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Novacyt	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk & volatility, EKF or NCYT?

EKF Diagnostics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Novacyt has a beta of -1.86, meaning that its share price is 286% less volatile than the S&P 500.

Which has preferable earnings and valuation, EKF or NCYT?

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£49.91M	1.96	£4.68M	£1.07	20.47
Novacyt	£18.12M	1.84	-£36.80M	-£54.44	-0.89

Summary

EKF Diagnostics beats Novacyt on 13 of the 14 factors compared between the two stocks.